Exchange: NYSE·Updated 03:54 PM EDT
News
all
press releases
Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA (copper intrauterine system) Risk Evaluation and Mitigation Strategy (REMS) Program is now open for enrollment at...
Business Wire
More News
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Organon (OGN) Lags Q2 Earnings Estimates
Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Organon Announces Quarterly Dividend
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the companys Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock...
Business Wire
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks
New Analysis of Phase 3 Pooled Data for Organons VTAMA (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety of VTAMA...
Business Wire
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon & Co. Shareholders Clear Sun Pharma Merger Deal...
Yahoo! Finance: News
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (SEC). The...
Business Wire
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Zacks
Organon to Present New Analysis on VTAMA (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in AD will be presented at the 2026 Society for Pediatric Dermatology (SPD) Annual...
Business Wire

Advertisement|Remove ads.